Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study
ID:am030003M0035287461cett34📫 -页
内容摘要
Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study
海外数据平台所有内容均是公开网络、AI代理代查、客户上传分享、合作方,仅供网友学习交流,请勿商用!

